FLT3 and acute myeloid leukemia: A system biology approach using whole-gene expression profiles to evaluate the potential benefits of the multi-target activity of potential FLT3 inhibitors for better understanding of their mechanism of action through molecular pathways and protein–protein interactions, as well as to check the treatment’s efficacy, i.e., their anti-leukemic effect on FLT3-mutated AML, seems promising [48,49,50,51,52].